This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: consensus

August 2017 Br J Cardiol 2017;24:(3) Online First

BCS 2017: spotlight on heart failure

BJC Staff, Dr Richard Crawley, Dr Brian Halliday, Dr Rosita Zakeri

Abstract

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began

| Full text
Neurohumoral activation in heart failure and the implications for treatment

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16 doi:10.5837/bjc.2016.s01

Neurohumoral activation in heart failure and the implications for treatment

Legate Philip, Paul R Kalra

Abstract

Introduction An acute pathological insult to the heart leads to a reduction in cardiac output (i.e. any cause of left ventricular systolic dysfunction [LVSD]), which activates a series of innate protective mechanisms. In the short term, activation of neurohumoral systems aim to preserve central arterial pressure and thereby vital organ perfusion, and include the sympathetic nervous system (SNS) and the renin–angiotensin–aldosterone system (RAAS). The net main effects of this process are: i) vasoconstriction; ii) sodium and water retention by the kidneys. While in the acute setting these adaptive responses may be beneficial, long-term over

| Full text
Decision by consensus: more political correctness or a genuine improvement in care?

November 2012 Br J Cardiol 2012;19:162-4

Decision by consensus: more political correctness or a genuine improvement in care?

Michael Norell

Abstract

You will not need to be reminded that our summer months (such as they were) were witness to a wealth of sporting endeavours. In addition to the ubiquitous and oft-repeated terms like ‘legacy’, ‘inspiration’ and ‘unbelievable’, the word team also enjoyed a reasonable airing. Extending the example of ‘Team-GB’, and employing a more cardiological perspective, I would submit the term ‘Team Heart’ for general consumption. Before readers assume that I am proposing a new Olympic competition in the form of the quickest call to balloon time, the largest number of new cardiac outpatients processed successfully in four hours, or the

| Full text
Chronic stable angina guidelines – is there an emerging international consensus?

August 2012 Br J Cardiol 2012;19(Suppl 2):S2–S11 doi:10.5837/bjc.2012.s06

Chronic stable angina guidelines – is there an emerging international consensus?

Professor Jose Lopez-Sendon, Dr Henry Purcell, Professor Paolo Camici, Dr Caroline Daly, Professor Jamil Mayet, Dr John Parissis, Professor Francesco Pelliccia, Professor Christophe Piot, Professor Rainer Hambrecht

Abstract

Introduction Stable angina is the most common manifestation of coronary heart disease. While considered relatively benign in terms of prognosis, the condition confers a higher risk of cardiovascular events than in the general population, with average annual mortality rates of 1–2%. Guidelines for the management of stable angina are relatively conservative in their approach, given their process of development. Moreover, stable angina management has not been as rigorously evaluated in large randomised trials as other coronary conditions. The role of newer treatment options in management algorithms also merits wider consideration. This expert

| Full text

August 2012 Br J Cardiol 2012;19:122–3 doi:10.5837/bjc.2012.020

Translating regulatory advice into practice: use of dronedarone and older anti-arrhythmics in AF management

A consensus position statement. A John Camm, Chris Arden, Anna-Maria Choy, Riyaz A Kaba, David Keane, Khalid Khan, Ernest Lau, Gregory Y H Lip, Francis Murgatroyd, G Andre Ng, Nicholas Peters, Henry Purcell, Peter Stafford, Neil Sulke, Helen Williams

Abstract

Introduction Patients with atrial fibrillation (AF) can benefit from rhythm management to improve unpleasant symptoms or increase exercise capacity,1 making anti-arrhythmic drugs (AADs) an important option in the management of AF. The benefits of any AAD must be weighed against the risks of adverse effects, which in some cases are serious. Defined indications for the use of AADs have been developed by regulatory bodies such as the European Medicines Agency (EMA) and US Food and Drug Administration (FDA), which, in addition to guidelines from groups such as the UK National Institute for Health and Clinical Excellence (NICE) and the European So

| Full text

May 2012

Position statement on anti-arrhythmic drugs

Abstract

Click to read the full article

| Full text
Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland

March 2010 Br J Cardiol 2010;17:76–80

Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland

Martin R Cowie, Paul O Collinson, Henry Dargie, FD Richard Hobbs, Theresa A McDonagh, Kenneth McDonald, Nigel Rowell

Abstract

(more…)

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now